NON-IMMUNOGENIC RECOMBINANT STAPHYLOKINASE VERSUS ALTEPLASE FOR PATIENTS WITH ACUTE ISCHAEMIC STROKE 4·5 H AFTER SYMPTOM ONSET IN RUSSIA (FRIDA): A RANDOMISED, OPEN LABEL, MULTICENTRE, PARALLEL-GROUP, NON-INFERIORITY TRIAL ArticleGusev E.I., Martynov M.Y., Nikonov A.A., Shamalov N.A., Semenov M.P., Gerasimets E.A., Yarovaya E.B., Semenov A.M., Archakov A.I., Markin S.S., Aksentiev S.B., Yunevich D.S., Alasheev A.M., Androfagina O.V., Bobkov V.V., Choroshavina K.V., Chefranova J.Y., Lykov Y.A., Chuprina S.E., Vorobev A.A. ...The Lancet Neurology. Том 20. 2021. С. 721-728
FORTELYZIN® IN COMPARISON WITH METALYSE® FOR ST-ELEVATED MYOCARDIAL INFARCTION: ONE-YEAR RESULTS AND CLINICAL OUTCOMES OF A MULTICENTER RANDOMIZED STUDY FRIDOM1 ArticleMarkov V.A., Duplyakov D.V., Konstantinov S.L., Klein G.V., Aksentev S.B., Platonov D.Y., Vyshlov E.V., Ponomarev E.A., Rabinovich R.M., Makarov E.L., Kulibaba E.V., Yunevich D.S., Kritskaia O.V., Baranov E.A., Talibov O.B., Gerasimets E.A.Российский кардиологический журнал. Том 23. 2018. С. 110-116
EXPERIMENTAL AND CLINICAL STUDIES OF STAPHYLOKINASE AND FORTELYZIN® ArticleVishlov E.V., Alekseeva Ya.V., Gerasimets E.A., Markov V.A.Кардиология: новости, мнения, обучение. 2017. С. 57-61
FORTELYZIN® VERSUS METALYSE® IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: RESULTS OF MULTICENTER RANDOMIZED TRIAL FRIDOM 1 TRIAL FRIDOM 1 TRIAL FRIDOM 1 ArticleMarkov V.A., Duplyakov D.V., Konstantinov S.L., Klein H.V., Aksentiev S.B., Platonov D.J., Vyashlov Eu.V., Ponomarev Ed.A., Rabinovich R.M., Makarov Eu.L., Kulibaba E.V., Krickaya O.V., Baranov Eu.A., Talibov O.B., Gerasimetc E.A.Кардиологический вестник. Том 12. 2017. С. 52-59